NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment

I-Mab's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink.

I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment
Credit: I-Mab
Already have an account? Sign in.
10/03/2025 · 7:07 AM
IMAB
/ Don’t stop at just one post.

Related↓

US Considers Major Curbs on Chinese Medicines
09/10/2025 · 3:00 PM

US Considers Major Curbs on Chinese Medicines

US may curb Chinese drugs over national security fears, with stricter reviews for deals/data. I-Mab stock fell but is a US firm. China's biotech role is growing. White House denies active consideration of draft order.

/ Subscriber only
/ Read more

Feed↓

FDA Panel Votes to Ease Access to Popular Peptide BPC-157
Featured/ 07/23/2026 · 2:37 PM

FDA Panel Votes to Ease Access to Popular Peptide BPC-157

FDA advisers voted 8-6 to let compounding pharmacies make the popular peptide BPC-157 with a prescription. Not full approval.

/ Subscriber only
RBC Sees Panama Expansion as Next Chapter in Bloom Energy–EdgeMode Partnership
Featured/ 07/23/2026 · 12:40 PM

RBC Sees Panama Expansion as Next Chapter in Bloom Energy–EdgeMode Partnership

RBC Capital highlights Bloom Energy’s likely role in EdgeMode’s 2.4 GW Panama fuel cell data centers and reiterates its Outperform rating with $335 target.

/ Subscriber only
Lockheed Martin Posts Blowout Quarter, Raises 2026 Guidance Amid Missile Restocking Boom
Featured/ 07/23/2026 · 12:11 PM

Lockheed Martin Posts Blowout Quarter, Raises 2026 Guidance Amid Missile Restocking Boom

Lockheed Martin drives defense sector gains with beat-and-raise Q2 earnings, record backlog, and higher 2026 outlook fueled by missile demand.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe